Neoadjuvant treatment of stage IIIA-N2 in
anaplastic lymphoma kinase (ALK)
early-stage
epidermal growth factor receptor (EGFR)
non-small cell lung cancer (NSCLC)
targeted therapy
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
12
2
2021
Statut:
ppublish
Résumé
Defining the optimal neoadjuvant strategy in early-stage and locoregional (N2) oncogenic-driven lung cancer remains a major challenge for the scientific community. Whereas significant advances have been achieved with the use of personalized medicine and targeted therapies in advanced stages, we are still far from translating the same magnitude of benefits into an earlier-stage disease. Perioperative strategies with neoadjuvant and adjuvant tyrosine kinase inhibitors in patients with
Identifiants
pubmed: 33569340
doi: 10.21037/tlcr-20-780
pii: tlcr-10-01-607
pmc: PMC7867758
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
607-621Informations de copyright
2021 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-780). The series “Multimodal management of locally advanced N2 non-small cell lung cancer” was commissioned by the editorial office without any funding or sponsorship. NR reports grants from Pfizer and Novartis; personal fees from MSD, BMS, Takeda, Roche, Boehringer Ingelheim, Astra Zeneca, Guardant Health, Novartis, Amgen and Lilly outside the submitted work. The authors have no other conflicts of interest to declare.
Références
J Thorac Oncol. 2017 Jul;12(7):1109-1121
pubmed: 28461257
J Clin Oncol. 2019 Sep 1;37(25):2235-2245
pubmed: 31194613
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
J Hematol Oncol. 2015 May 17;8:54
pubmed: 25981169
J Natl Cancer Inst. 2007 Mar 21;99(6):442-50
pubmed: 17374834
Oncologist. 2019 Feb;24(2):157-e64
pubmed: 30158288
Ann Thorac Surg. 2014 Apr;97(4):1156-62
pubmed: 24582052
Thorac Cancer. 2018 Jul;9(7):814-819
pubmed: 29722148
Lancet Oncol. 2020 Jun;21(6):786-795
pubmed: 32386568
J Thorac Dis. 2017 Dec;9(12):5314-5321
pubmed: 29312741
Transl Lung Cancer Res. 2015 Apr;4(2):191-7
pubmed: 25870801
Ann Surg Oncol. 2014 Jun;21(6):2091-6
pubmed: 24585406
J Thorac Oncol. 2010 Apr;5(4):510-6
pubmed: 20107424
J Thorac Dis. 2020 Apr;12(4):1615-1620
pubmed: 32395299
Cancer Manag Res. 2018 Sep 10;10:3393-3404
pubmed: 30237741
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Eur J Cardiothorac Surg. 2016 Aug;50(2):322-8
pubmed: 26920941
PLoS One. 2015 Oct 16;10(10):e0140794
pubmed: 26474174
J Clin Oncol. 2014 Sep 1;32(25):2780-7
pubmed: 25071109
JAMA. 2012 Mar 28;307(12):1265-72
pubmed: 22453568
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
J Thorac Dis. 2016 Nov;8(Suppl 11):S849-S854
pubmed: 27942406
Clin Cancer Res. 2015 Dec 15;21(24):5439-44
pubmed: 26672084
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Lancet Respir Med. 2018 Nov;6(11):863-873
pubmed: 30150014
Clin Lung Cancer. 2020 Jul;21(4):341-348
pubmed: 32279936
J Thorac Oncol. 2019 Apr;14(4):726-731
pubmed: 30408570
J Clin Oncol. 2013 Sep 20;31(27):3320-6
pubmed: 23980091
Ann Thorac Surg. 2019 Jun;107(6):1866-1875
pubmed: 30557543
Am J Clin Oncol. 2014 Aug;37(4):343-9
pubmed: 23357969
Ann Oncol. 2019 May 1;30(5):839-844
pubmed: 30847464
Am Soc Clin Oncol Educ Book. 2020 May;40:372-384
pubmed: 32421452
JCO Precis Oncol. 2018 Nov;2:1-18
pubmed: 35135121
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
J Thorac Cardiovasc Surg. 2016 May;151(5):1235-8
pubmed: 26997100
J Thorac Oncol. 2012 Jan;7(1):90-7
pubmed: 22134072
Cancer Manag Res. 2020 Jan 24;12:589-598
pubmed: 32158263
Ann Thorac Surg. 2013 Sep;96(3):962-8
pubmed: 23932319
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
J Thorac Cardiovasc Surg. 2021 Feb;161(2):434-442.e2
pubmed: 32340810
Lung Cancer. 2017 Oct;112:1-9
pubmed: 29191580
Ann Thorac Surg. 2015 Nov;100(5):1773-9
pubmed: 26228601
J Clin Oncol. 2015 Dec 1;33(34):4007-14
pubmed: 26324372
N Engl J Med. 2018 Mar 1;378(9):869-870
pubmed: 29490170
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333
Ann Oncol. 2013 May;24(5):1319-25
pubmed: 23277484
Lancet. 2014 May 3;383(9928):1561-71
pubmed: 24576776
Ann Surg Oncol. 2017 Mar;24(3):770-777
pubmed: 27696172
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
J Thorac Oncol. 2012 Dec;7(12):1815-1822
pubmed: 23154553
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Lung Cancer. 2014 Mar;83(3):389-95
pubmed: 24462463
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
N Engl J Med. 2018 Mar 29;378(13):1262-1263
pubmed: 29590540
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Lancet Oncol. 2008 Jul;9(7):636-48
pubmed: 18583190
J Thorac Oncol. 2013 Feb;8(2):171-8
pubmed: 23287850
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Ann Oncol. 2018 Jan 1;29(1):200-208
pubmed: 29186353
Lancet Oncol. 2018 Jan;19(1):139-148
pubmed: 29174310
J Thorac Oncol. 2014 Jun;9(6):805-11
pubmed: 24787964
Br J Cancer. 2006 Apr 24;94(8):1099-106
pubmed: 16622435
J Thorac Oncol. 2019 Apr;14(4):606-616
pubmed: 30605727
J Clin Oncol. 1993 Sep;11(9):1757-62
pubmed: 8394881
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
J Thorac Oncol. 2020 May;15(5):709-740
pubmed: 32004713
J Clin Oncol. 2003 May 1;21(9):1752-9
pubmed: 12721251
J Clin Oncol. 2019 Jan 10;37(2):97-104
pubmed: 30444685
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378